Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH

Walleye Capital LLC purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 17,881 shares of the company’s stock, valued at approximately $1,743,000.

Other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics in the second quarter worth about $27,000. First Horizon Corp purchased a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $40,000. Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Anne Mcgeorge sold 7,750 shares of Dianthus Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the transaction, the director owned 1,250 shares of the company’s stock, valued at $136,262.50. The trade was a 86.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the transaction, the chief executive officer owned 65,292 shares in the company, valued at approximately $7,058,718.12. The trade was a 71.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 284,306 shares of company stock valued at $29,289,369. 3.02% of the stock is currently owned by insiders.

Dianthus Therapeutics Stock Up 5.8%

Dianthus Therapeutics stock opened at $115.96 on Friday. The company has a market capitalization of $6.34 billion, a P/E ratio of -27.94 and a beta of 1.22. The stock’s 50 day moving average is $97.47 and its 200 day moving average is $82.85. Dianthus Therapeutics, Inc. has a twelve month low of $19.84 and a twelve month high of $116.47.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Truist Financial increased their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. HC Wainwright raised their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wedbush raised their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Finally, Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $124.27.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.